Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine hydrochloride is a selective α1‑adrenergic receptor agonist. When applied to the eye, it contracts the radial iris dilator muscle, pulling the iris outward and contributing to pupil enlargement. In Mydriasert, this effect is complemented by tropicamide’s antimuscarinic action.

The dosing regimen for Mydriasert is determined by the prescribing eye‑care professional. Typically, one drop is instilled in the conjunctival sac of each eye, but the exact number of drops, timing, and frequency depend on the specific clinical situation.

Safety data for Mydriasert in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Mydriasert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mydriasert combines two mechanisms—α1‑adrenergic stimulation and antimuscarinic blockade—offering faster onset and longer duration of dilation than single‑agent drops such as phenylephrine alone or tropicamide alone. This dual action can reduce the need for repeat dosing in many procedures.

Store Mydriasert at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light and moisture, and ensure the cap is tightly closed when not in use.

Mydriasert is applied topically to the eye. The prescriber typically instructs the patient or clinician to place one drop into the conjunctival sac of each eye, avoiding contact with the eyelid or lashes, and to wait the recommended interval before any further ocular manipulation.

The most serious adverse events include acute angle‑closure glaucoma, marked systemic hypertension, severe ocular pain, and allergic contact dermatitis. Patients should be monitored for signs of increased intra‑ocular pressure or systemic cardiovascular changes, especially if they have pre‑existing risk factors.

Mydriasert should be avoided in individuals with known hypersensitivity to phenylephrine, tropicamide, or any excipients, as well as in patients with narrow‑angle or uncontrolled glaucoma, severe cardiovascular disease, or those taking contraindicated systemic sympathomimetics.